{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:54:26Z","timestamp":1784120066709,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014069","name":"Funda\u00e7\u00e3o Champalimaud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102141","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:26:01Z","timestamp":1772641561000},"page":"102141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions"],"prefix":"10.1016","volume":"28","author":[{"given":"Lucas C.M.","family":"Arruda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Karbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Kiselicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgueni","family":"Sinelnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Gustavus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Atmaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102141_bib0001","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","article-title":"Pancreatic cancer","volume":"405","author":"Stoop","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2026.102141_bib0002","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.cell.2023.02.014","article-title":"Pancreatic cancer: advances and challenges","volume":"186","author":"Halbrook","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2026.102141_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmolb.2022.1020888","article-title":"Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: tumour microenvironment components","volume":"9","author":"Hsu","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jcyt.2026.102141_bib0004","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0005","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.jcyt.2026.102141_bib0006","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0007","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0008","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO.20.02232","article-title":"Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA)","volume":"39","author":"Hecht","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-L (HyperAcute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.jcyt.2026.102141_bib0010","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41586-022-04735-9","article-title":"Neoantigen quality predicts immunoediting in survivors of pancreatic cancer","volume":"606","author":"\u0141uksza","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102141_bib0012","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102141_bib0013","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102141_bib0014","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40291-024-00708-y","article-title":"Lifileucel: first approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.jcyt.2026.102141_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41587-024-02232-0","article-title":"Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms","volume":"43","author":"P\u00e9tremand","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0017","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","article-title":"Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer","volume":"24","author":"Zacharakis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0018","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1084\/jem.20060710","article-title":"Random migration precedes stable target cell interactions of tumor-infiltrating T cells","volume":"203","author":"Mrass","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0019","first-page":"1","article-title":"The critical role of homing in TIL therapy success: from biology to clinical application","author":"Mohammadi","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0020","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/bjc.2013.32","article-title":"Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer","volume":"108","author":"Ino","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcyt.2026.102141_bib0021","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/2767-9764.CRC-23-0405","article-title":"Exhausted tumor-infiltrating CD39+CD103+ CD8+ T cells unveil potential for increased survival in human pancreatic cancer","volume":"4","author":"Gorchs","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jcyt.2026.102141_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15095","article-title":"Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer","volume":"8","author":"Carstens","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102141_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2023-006822","article-title":"Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma","volume":"12","author":"Amaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102141_bib0024","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jcyt.2024.12.010","article-title":"Entering a new era of tumor-infiltrating lymphocyte cell therapy innovation","volume":"27","author":"Amaria","year":"2025","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102141_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005847","article-title":"Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer","volume":"11","author":"Karbach","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102141_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2025.2559784","article-title":"Tumor-infiltrating lymphocytes-derived CD8+ clonotypes infiltrate the tumor tissue and mediate tumor regression in glioblastoma","volume":"14","author":"Arruda","year":"2025","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jcyt.2026.102141_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1693912","article-title":"Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer","volume":"15","author":"Arruda","year":"2025","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0028","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jcyt.2023.01.009","article-title":"Generation of colon cancer\u2013derived tumor-infiltrating T cells (TILs) for adoptive cell therapy","volume":"25","author":"Albrecht","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102141_bib0029","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/nar\/gkp1137","article-title":"The sanger FASTQ file format for sequences with quality scores, and the Solexa\/Illumina FASTQ variants","volume":"38","author":"Cock","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcyt.2026.102141_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/1471-2105-15-182","article-title":"Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads","volume":"15","author":"Jiang","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jcyt.2026.102141_bib0031","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1093\/bioinformatics\/btr330","article-title":"The variant call format and VCFtools","volume":"27","author":"Danecek","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcyt.2026.102141_bib0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41416-018-0262-z","article-title":"Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer","volume":"120","author":"Meng","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jcyt.2026.102141_bib0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jcyt.2026.102141_bib0034","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcyt.2026.102141_bib0036","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.jcyt.2026.102141_bib0037","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0038","doi-asserted-by":"crossref","first-page":"19469","DOI":"10.18632\/oncotarget.24955","article-title":"Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma","volume":"9","author":"Valentini","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jcyt.2026.102141_bib0039","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/nbt.2938","article-title":"Linking T-cell receptor sequence to functional phenotype at the single-cell level","volume":"32","author":"Han","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0040","doi-asserted-by":"crossref","first-page":"W534","DOI":"10.1093\/nar\/gkaf388","article-title":"TIMER3: an enhanced resource for tumor immune analysis","volume":"53","author":"Cui","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jcyt.2026.102141_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"10.1016\/j.jcyt.2026.102141_bib0042","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.jcyt.2026.102141_bib0043","first-page":"1","article-title":"Role of FHOD1 in tumor cells and tumor immune microenvironment","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0044","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41419-021-03707-7","article-title":"ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jcyt.2026.102141_bib0045","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.15613","article-title":"TMEM200A is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer","volume":"11","author":"Fang","year":"2023","journal-title":"Peer J"},{"key":"10.1016\/j.jcyt.2026.102141_bib0046","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90077-x","article-title":"ITGA2, LAMB3, and LAMC2 may be the potential therapeutic targets in pancreatic ductal adenocarcinoma: an integrated bioinformatics analysis","volume":"11","author":"Islam","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcyt.2026.102141_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.914956","article-title":"C1QTNF3 is upregulated during subcutaneous adipose tissue remodeling and stimulates macrophage chemotaxis and M1-like polarization","volume":"13","author":"Micallef","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0048","article-title":"Protein-coupled Receptors","volume":"234","author":"Aust","year":"2016"},{"key":"10.1016\/j.jcyt.2026.102141_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10565-021-09671-4","article-title":"YEATS2 regulates the activation of TAK1\/NF-\u03baB pathway and is critical for pancreatic ductal adenocarcinoma cell survival","volume":"39","author":"Sheng","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40001-025-02326-8","article-title":"Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jcyt.2026.102141_bib0051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1010428317694304","article-title":"CDK9 is a prognostic marker and therapeutic target in pancreatic cancer","volume":"39","author":"Kretz","year":"2017","journal-title":"Tumor Biol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2021.762233","article-title":"Oxysterol-binding protein 2 promotes pancreatic ductal adenocarcinoma progression through epithelial-mesenchymal transition","volume":"11","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0053","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccell.2017.07.007","article-title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","volume":"32","author":"Raphael","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2026.102141_bib0054","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","article-title":"Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes","volume":"186","author":"Rahim","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2026.102141_bib0055","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jcyt.2026.102141_bib0056","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/s41467-018-05072-0","article-title":"Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors","volume":"9","author":"Duhen","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102141_bib0057","doi-asserted-by":"crossref","first-page":"abe6474","DOI":"10.1126\/science.abe6474","article-title":"Pan-cancer single-cell landscape of tumor-infiltrating T cells","volume":"374","author":"Zheng","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jcyt.2026.102141_bib0058","first-page":"92","article-title":"Recent advancements in nanomedicine for \u2018cold\u2019 tumor immunotherapy","volume":"13","author":"Chen","year":"2021","journal-title":"Nanomicro Lett"},{"key":"10.1016\/j.jcyt.2026.102141_bib0059","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41540-024-00355-3","article-title":"Making drugs from T cells: the quantitative pharmacology of engineered T cell therapeutics","volume":"10","author":"Kirouac","year":"2024","journal-title":"NPJ Syst Biol Appl"},{"key":"10.1016\/j.jcyt.2026.102141_bib0060","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","author":"Witkiewicz","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102141_bib0061","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPA.0b013e31825b6ab0","article-title":"Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival","volume":"42","author":"Shin","year":"2013","journal-title":"Pancreas"},{"key":"10.1016\/j.jcyt.2026.102141_bib0062","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-11-0269","article-title":"Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy","volume":"10","author":"Kim","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jcyt.2026.102141_bib0063","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-021-02225-w","article-title":"The path to the clinic: a comprehensive review on direct KRASG12C inhibitors","volume":"41","author":"Kwan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102141_bib0064","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","article-title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","volume":"14","author":"Lu","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102141_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2018.e01055","article-title":"Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype","volume":"4","author":"Swayden","year":"2018","journal-title":"Heliyon"},{"key":"10.1016\/j.jcyt.2026.102141_bib0066","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1038\/s41588-024-01914-4","article-title":"Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity","volume":"56","author":"Khaliq","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.jcyt.2026.102141_bib0067","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006666","article-title":"TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma","volume":"11","author":"Shi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102141_bib0068","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in anti\u2013PD-1 na\u00efve and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcyt.2026.102141_bib0069","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/s41467-017-01460-0","article-title":"Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma","volume":"8","author":"Lauss","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jcyt.2026.102141_bib0070","doi-asserted-by":"crossref","first-page":"eado2402","DOI":"10.1126\/scitranslmed.ado2402","article-title":"Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy","volume":"16","author":"Liu","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0071","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102141_bib0072","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jcyt.2026.102141_bib0073","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2026.102141_bib0074","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.jcyt.2026.102141_bib0075","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.jcyt.2026.102141_bib0076","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jcyt.2026.102141_bib0077","article-title":"Clinical and molecular dissection of CAR T cell resistance in pancreatic cancer","volume":"6","author":"Aznar","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jcyt.2026.102141_bib0078","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jcyt.2026.102141_bib0079","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-013420","article-title":"The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee","volume":"13","author":"Coukos","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102141_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2024-010207","article-title":"Art of TIL immunotherapy: SITC\u2019s perspective on demystifying a complex treatment","volume":"13","author":"Turcotte","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jcyt.2026.102141_bib0081","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.trecan.2025.08.002","article-title":"Immune correlates and mechanisms of TIL therapy efficacy: current insights and knowledge gaps","volume":"11","author":"Navarro Rodrigo","year":"2025","journal-title":"Trends Cancer"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926001027?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926001027?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:19:49Z","timestamp":1781018389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926001027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926001027"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102141","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting intratumoral heterogeneity in pancreatic cancer with sequential TIL infusions","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the International Society for Cellular Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102141"}}